CIK 0000842023 · Large accelerated filer
BIO-TECHNE Corp
Sign in to watch- Ticker
- TECH
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jun 30
- Incorporated
- MN
- Entity type
- operating
- EIN
- 411427402
- Phone
- 612-379-8854
- Business address
- 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN
- Former names
- TECHNE CORP /MN/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-08-15 | Kummeth Charles R. Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | +300,000 | 300,000 | ||
| 2022-08-15 | Furlow Brenda S. SVP - General Counsel | Grant or award · Stock Options (Right to Buy) | +6,166 | 6,166 | ||
| 2022-08-15 | Furlow Brenda S. SVP - General Counsel | Grant or award · Restricted Stock Units | +1,984 | 1,984 | ||
| 2022-08-15 | Geist William PRESIDENT, PROTEIN SCIENCES | Grant or award · Restricted Stock Units | +1,785 | 1,785 | ||
| 2022-08-15 | Geist William PRESIDENT, PROTEIN SCIENCES | Grant or award · Stock Options (Right to Buy) | +5,550 | 5,550 | ||
| 2022-08-15 | Geist William PRESIDENT, PROTEIN SCIENCES | Grant or award · Stock Options (Right to Buy) | +7,400 | 7,400 | ||
| 2022-08-15 | Kelderman Kim PRES. DIAGNOSTICS & GENOM | Grant or award · Restricted Stock Units | +1,746 | 1,746 | ||
| 2022-08-15 | Kelderman Kim PRES. DIAGNOSTICS & GENOM | Grant or award · Stock Options (Right to Buy) | +5,426 | 5,426 | ||
| 2022-08-15 | Kelderman Kim PRES. DIAGNOSTICS & GENOM | Grant or award · Stock Options (Right to Buy) | +7,235 | 7,235 | ||
| 2022-08-15 | Hippel James CFO | Grant or award · Restricted Stock Units | +2,728 | 2,728 | ||
| 2022-08-15 | Hippel James CFO | Grant or award · Stock Options (Right to Buy) | +8,479 | 8,479 | ||
| 2022-08-15 | Hippel James CFO | Grant or award · Stock Options (Right to Buy) | +11,305 | 11,305 | ||
| 2022-08-11 | HIGGINS JOHN L Director | Sale | −504 | $385.47 | $194K | 5,510 |
| 2022-08-11 | HIGGINS JOHN L Director | Sale | −8 | $380.71 | $3K | 5,502 |
| 2022-08-10 | HIGGINS JOHN L Director | Option exercise | +3,400 | $66.90 | $227K | 8,006 |
| 2022-08-10 | HIGGINS JOHN L Director | Sale | −900 | $373.99 | $337K | 7,106 |
| 2022-08-10 | HIGGINS JOHN L Director | Sale | −100 | $374.90 | $37K | 7,006 |
| 2022-08-10 | HIGGINS JOHN L Director | Sale | −992 | $380.15 | $377K | 6,014 |
| 2022-08-10 | HIGGINS JOHN L Director | Option exercise · Stock Option (right to buy) | −3,400 | 0 | ||
| 2022-08-08 | Furlow Brenda S. SVP - General Counsel | Option exercise | +563 | $177.32 | $100K | 6,523 |
Page 23 of 32 · 626 trades